Michelle Naiying Yang

Michelle Naiying Yang is an experienced professional in the field of biochemistry and molecular biology, currently serving as Associate Director and Clinical Biomarker Lead at REVOLUTION Medicines since June 2022. Prior to this role, Michelle worked at Genentech for eight years, progressing from Senior Research Associate to Principal Scientific Researcher, where responsibilities included managing resources and advising on oncology projects. Previous experiences include a Senior Research Associate position at CytomX Therapeutics, a focus on combination therapies at Genentech, and a postdoctoral associate position at The Burnham Institute, where significant contributions to cancer research were published. Michelle also holds a PhD in Biochemistry and Molecular Biology from the University of California, Riverside, and a B.S. in Biochemical Science and Technology from National Taiwan University.